Tamoxifen & Aromatase Inhibitor Therapy

For patients with hormone receptor-positive (ER+/PR+) breast cancer, endocrine therapy is a cornerstone of long-term management. Tamoxifen (a selective oestrogen receptor modulator) is used in pre-menopausal women for 5–10 years. Aromatase Inhibitors — Anastrozole, Letrozole and Exemestane — are preferred in post-menopausal women and have superior efficacy in that setting. At our centre, Dr. Joshi guides the choice of agent based on menopausal status, bone density, cardiovascular risk and tolerability. Long-term management includes bone health monitoring (DEXA scan, calcium and Vitamin D supplementation) and management of menopausal side effects. CDK 4/6 inhibitors (Palbociclib, Ribociclib) are added in metastatic or high-risk disease.

📋 Treatment Overview

📅 Schedule a Consultation

Talk to Dr. Joshi about whether this treatment is right for you. OPD: Mon–Thu, 10 AM – 1 PM.